You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of recombinant VSV vaccines for emerging bunyaviruses

    SBC: Advac Therapeutic LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Emerging viral infections remain a global threat to human health. Bunyaviruses are the largest order of RNA viruses that includes many clinically relevant human pathogens such as Lassa, Rift Valley Fever and various hantaviruses which cause viral hemorrhagic fever (VHF). SFTSV, or Severe fever with thrombocytopenia syndrome virus, is an emerging tick-borne bunyavirus that ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. TeleLine: Plug-n-Play Inline Respiratory Remote Data Acquisition System

    SBC: OMNIBUS MEDICAL DEVICES, LLC            Topic: NINR

    Project Summary One in five Americans live in a rural community served by rural hospitals yet only 1% of ICU resources are available to these hospitals. When the level of care required by a patient exceeds the capabilities of the admitting hospital, the patient is transferred to a better-equipped tertiary hospital. Approximately 800,000 patients require mechanical ventilation every year in the Uni ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease

    SBC: FURANICA, INC.            Topic: NHLBI

    1 Project Summary2 Cardiovascular risks in dyslipidemia patients are commonly controlled by lowering the LDL-C level using statins.3 However, a significant residual cardiovascular risk persists in patients with additional concurrent risk factors such4 as obesity, diabetes, insulin resistance, and elevated triglyceride-rich lipoproteins. Given the multifaceted5 underlying pathology of cardiovascula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. The DOVE Device to Prevent Opioid Overdose Deaths: An Armband That Senses Overdose and Automatically Injects Naloxone

    SBC: Altrumed LLC            Topic: NIDA

    ABSTRACT / PROJECT SUMMARY Despite the wide availability of the antidote naloxone, fatal opioid overdoses still occur at a rate of ~50-70,000 / year in the US. The problem is that naloxone requires a bystander to find and diagnose the overdose, find someone who has naloxone, and then properly administer it. Unfortunately, if this does not occur within 5 minutes, the patient will suffer from brain ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Optimizing the synthesis of[18F]FTMP for commercial distribution

    SBC: VELLUM BIOSCIENCES LLC            Topic: NIBIB

    Abstract The development of genetic medicines such as gene and cell therapies like Chimeric Antigen Receptor (CAR) T cells has necessitated new technologies that can monitor the biodistribution of these therapies in human patients. Imaging is particularly well suited to provide such quantitative measurements of a genetic medicine over time. Vellum Biosciences is a platform imaging company geared t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk

    SBC: MOLECULAR TARGETING TECHNOLOGIES, INC.            Topic: NHLBI

    We propose to develop a novel antithrombotic agent with improved efficacy and safety over standard of care via the following properties: 1) specific targeting to procoagulant surfaces, 2) high coagulant site binding and blocking capacity, 3) potent and specific effects of reducing clot size by selectively blocking only highly coagulant sites, 4) reducing bleeding risk compared with current antipla ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Biomimetic Stentless Pulmonary Heart Valve for the Treatment of Pediatric Congenital Heart Disease

    SBC: NEOOLIFE, INC.            Topic: NHLBI

    PROJECT SUMMARY Congenital heart disease (CHD) is caused by defects in the heart structure that occur at birth and affect blood flow through the heart and the rest of the body. CHD affects around 10 out of 1,000 live-born children, 25% of which will need an intervention or surgery within their first year of life. Circa 1 million children and 1.4 million adults live with CHD in the US, and over 182 ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection

    SBC: HARLINGENE LIFE SCIENCES LLC            Topic: NIAID

    Hepatoselective Dihydroquinolizinone (HS-HS-DHQ) Molecules for Treatment and Preventionof Hepatitis A Virus Infection ABSTRACT This is a Phase I proposal to develop Harlingene’s hepatoselective dihydroquinolizinones (HS- DHQs) for treatment and prevention of hepatitis A virus (HAV) infection. This will be the first antiviral therapy to treat HAV infection, which, despite vaccines to prevent dise ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Epigenetic Modifiers to treat Photoreceptor Degenerations

    SBC: SKYRAN BIOLOGICS, INC.            Topic: NEI

    Abstract:The overall goal of Skyran Biologics is to develop powerful topical therapeutics to combat retinal degenerative diseases. In the course of our studies on epigenetic regulation of retinal development we have defined ways in which histone modifications can lock genes encoding these mechanisms into inactive, condensed chromatin. We found a number of drugs that partially reverse chromatin con ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Restoration of Muscular Function Following Direct Muscle Neurotization

    SBC: Renerva, LLC            Topic: 107

    Summary/Abstract More than 500,000 surgical procedures are performed annually in the US to address peripheral nerve injury (PNI), at a cost of more than $1.1B. PNI and their sequelae affect more than 20 million Americans, with total economic impacts in excess of $150B annually. Despite advances in microsurgical techniques and the inherent ability of the peripheral nervous system to regenerate, few ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government